The FDA also granted orphan status to two drugs: Cypros Pharmaceuticals' (CYP) Ceresine
, a drug that reduces the accumulation of lactic acid in the brain occurring after a stroke or brain injury; and Immunomedics's (IMMU) yttrium-90-radiolabled CEA-Cide cancer therapeutic for use in ovarian cancer.
Furthermore, Cypros' new drugs, Ceresine
and Cordox, one of which is in Phase III of the clinical trial process, address ischemia, the number one cause of death in developed countries.
This status is in addition to the expedited status previously granted to Cypros for the drug Ceresine
, the company's other late stage drug, which also protects cells from ischemia.
Cypros is developing Cordox (R) (formerly CPC-111) and Ceresine (R) (formerly CPC-211) to combat the problem of ischemia.
Ceresine is a compound that can cross the blood-brain barrier, a selective protection system that protects the brain.